Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL5328781 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL6365 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL10336277 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL26077 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL17164701 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL4019370 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL7744729 | 0.98 | ESR1 (0.96) | ESR1ESR2MEN1TP53KMT2A | |
| Tamoxifen SCHEMBL5322913 | 0.97 | ESR1 (0.94) | ESR1ESR2MEN1TP53KMT2A | |
| SCHEMBL4104443 | 0.94 | ESR1 (0.89) | ESR1ESR2MEN1TP53KMT2A | |
| Toremifene SCHEMBL21464516 | 0.93 | ESR1 (0.87) | ESR1ESR2MEN1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2591 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-12043667-B2 | CLEC12a binding polypeptides and uses thereof | INHIBRX BIOSCIENCES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240240147-A1 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-07-18 | — | — | US | disclosed |
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240226317-A9 | ANTIBODY-DRUG CONJUGATES TARGETING uPARAP | RIGSHOSPITALET (DK) | 2024-07-11 | — | — | US | disclosed |
| US-20240228653-A1 | PSGL-1 Antagonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228664-A9 | Antibodies Binding to Human PAD4 and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2005012531-A2 | ANTIBODY CDR POLYPEPTIDE SEQUENCES WITH RESTRICTED DIVERSITY | GENENTECH, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005002582-A2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003154-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005001486-A1 | MODULATING THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000900-A1 | TREATMENT WITH ANTI-VEGF ANTIBODIES | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004094476-A2 | COMPOSITIONS AND METHODS RELATING TO STOP-1 | GENENTECH, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004029295-A1 | METHOD FOR DIAGNOSIS OF CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2004-04-08 | — | — | WO | disclosed |
| US-20030158160-A1 | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030092631-A1 | IGF antagonist peptides | GENENTECH, INC. | 2003-05-15 | — | — | US | disclosed |